Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 436123, 6 pages
http://dx.doi.org/10.1155/2014/436123
Review Article

Nonsteroidal Anti-Inflammatory Drugs and Prostatic Diseases

1Photocatalyst Group, Kanagawa Academy of Science and Technology, 3-25-13 Tonomachi, Kawasaki-ku, Kanagawa, Kawasaki 210-0821, Japan
2Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Kanagawa, Yokohama 236-0004, Japan

Received 15 December 2013; Accepted 22 April 2014; Published 12 May 2014

Academic Editor: Paul Crispen

Copyright © 2014 Hitoshi Ishiguro and Takashi Kawahara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Schrecengost and K. E. Knudsen, “Molecular pathogenesis and progression of prostate cancer,” Seminars in Oncology, vol. 40, no. 3, pp. 244–258, 2013. View at Publisher · View at Google Scholar
  2. G. Penna, N. Mondaini, S. Amuchastegui et al., “Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia,” European Urology, vol. 51, no. 2, pp. 524–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Macoska, “Chemokines and BPH/LUTS,” Differentiation, vol. 82, no. 4-5, pp. 253–260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Cai, S. Mazzoli, F. Meacci et al., “Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis,” The Journal of Microbiology, vol. 49, no. 3, pp. 448–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. R. Vane, “Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs,” Nature, vol. 231, no. 25, pp. 232–235, 1971. View at Google Scholar · View at Scopus
  6. R. N. DuBois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” The FASEB Journal, vol. 12, no. 12, pp. 1063–1073, 1998. View at Google Scholar · View at Scopus
  7. J. R. Vane, Y. S. Bakhle, and R. M. Botting, “Cyclooxygenases 1 and 2,” Annual Review of Pharmacology and Toxicology, vol. 38, pp. 97–120, 1998. View at Google Scholar · View at Scopus
  8. C. Bombardier, L. Laine, A. Reicin et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” The New England Journal of Medicine, vol. 343, no. 21, pp. 1520–1528, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1092–1102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Rigas and K. Kashfi, “Nitric-oxide-donating NSAIDs as agents for cancer prevention,” Trends in Molecular Medicine, vol. 10, no. 7, pp. 324–330, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. N. Krieger, L. Nyberg Jr., and J. C. Nickel, “NIH consensus definition and classification of prostatitis,” The Journal of the American Medical Association, vol. 282, no. 3, pp. 236–237, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Canale, I. Scaricabarozzi, P. Giorgi, P. Turchi, M. Ducci, and G. F. Menchini-Fabris, “Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis,” Andrologia, vol. 25, no. 3, pp. 163–166, 1993. View at Google Scholar · View at Scopus
  13. J. C. Nickel, M. Pontari, T. Moon et al., “A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis,” The Journal of Urology, vol. 169, no. 4, pp. 1401–1405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. K. Parsons, “Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors,” Current Bladder Dysfunction Reports, vol. 5, no. 4, pp. 212–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Nickel, “Inflammation and benign prostatic hyperplasia,” Urologic Clinics of North America, vol. 35, no. 1, pp. 109–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Chughtai, R. Lee, A. Te, and S. Kaplan, “Role of inflammation in benign prostatic hyperplasia,” Reviews in Urology, vol. 13, no. 3, pp. 147–150, 2011. View at Google Scholar
  17. P. W. Kohnen and G. W. Drach, “Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study,” The Journal of Urology, vol. 121, no. 6, pp. 755–760, 1979. View at Google Scholar · View at Scopus
  18. F. di Silverio, V. Gentile, A. de Matteis et al., “Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis,” European Urology, vol. 43, no. 2, pp. 164–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. G. E. Steiner, M. E. Newman, D. Paikl et al., “Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate,” The Prostate, vol. 56, no. 3, pp. 171–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. G. P. O'Neill and A. W. Ford-Hutchinson, “Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues,” FEBS Letters, vol. 330, no. 2, pp. 156–160, 1993. View at Google Scholar · View at Scopus
  21. A. Kirschenbaum, A. P. Klausner, R. Lee et al., “Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate,” Urology, vol. 56, no. 4, pp. 671–676, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. L.-M. Lee, C.-C. Pan, C.-J. Cheng, C.-W. Chi, and T.-Y. Liu, “Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia,” Anticancer Research, vol. 21, no. 2, pp. 1291–1294, 2001. View at Google Scholar · View at Scopus
  23. W. Wang, A. Bergh, and J.-E. Damber, “Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium,” The Prostate, vol. 61, no. 1, pp. 60–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. F. di Silverio, C. Bosman, M. Salvatori et al., “Combination therapy with rofecoxib and finasteride in the treatment of men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH),” European Urology, vol. 47, no. 1, pp. 72–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Ozdemir, O. Bozkurt, O. Demir, G. Aslan, and A. A. Esen, “Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms,” Urology, vol. 74, no. 2, pp. 431–435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-F. Jhang, Y.-H. Jiang, and H.-C. Kuo, “Adding cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms,” International Journal of Clinical Practice, vol. 67, no. 12, pp. 1327–1333, 2013. View at Publisher · View at Google Scholar
  27. M. Kaye, “Aging, circadian weight change, and nocturia,” Nephron Physiology, vol. 109, no. 1, pp. p11–p18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. St. Sauver, D. J. Jacobson, M. E. Mcgree, M. M. Lieber, and S. J. Jacobsen, “Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia,” American Journal of Epidemiology, vol. 164, no. 8, pp. 760–768, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Falahatkar, G. Mokhtari, F. Pourreza, S. A. Asgari, and A. N. Kamran, “Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study,” Urology, vol. 72, no. 4, pp. 813–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Kahokehr, R. Vather, A. Nixon, and A. G. Hill, “Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials,” BJU International, vol. 111, no. 2, pp. 304–311, 2013. View at Publisher · View at Google Scholar
  31. J. M. Schenk, G. S. Calip, C. M. Tangen et al., “Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial,” American Journal of Epidemiology, vol. 176, no. 2, pp. 156–163, 2012. View at Publisher · View at Google Scholar
  32. J. B. Meigs, B. Mohr, M. J. Barry, M. M. Collins, and J. B. McKinlay, “Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men,” Journal of Clinical Epidemiology, vol. 54, no. 9, pp. 935–944, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Kang, G. L. Andriole, R. C. van de Vooren et al., “Risk behaviours and benign prostatic hyperplasia,” BJU International, vol. 93, no. 9, pp. 1241–1245, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. K. M. C. Verhamme, J. P. Dieleman, M. A. M. van Wijk et al., “Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention,” Archives of Internal Medicine, vol. 165, no. 13, pp. 1547–1551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. C. H. Minnery and R. H. Getzenberg, “Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen,” The Journal of Urology, vol. 174, no. 1, pp. 375–379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Altavilla, L. Minutoli, F. Polito et al., “Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia,” British Journal of Pharmacology, vol. 167, no. 1, pp. 95–108, 2012. View at Publisher · View at Google Scholar
  37. E. Kashiwagi, M. Shiota, A. Yokomizo et al., “Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells,” Endocrine-Related Cancer, vol. 20, no. 3, pp. 431–441, 2013. View at Publisher · View at Google Scholar
  38. A. M. de Marzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. K. S. Sfanos and A. M. de Marzo, “Prostate cancer and inflammation: the evidence,” Histopathology, vol. 60, no. 1, pp. 199–215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Haverkamp, B. Charbonneau, and T. L. Ratliff, “Prostate inflammation and its potential impact on prostate cancer: a current review,” Journal of Cellular Biochemistry, vol. 103, no. 5, pp. 1344–1353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Gupta, M. Srivastava, N. Ahmad, D. G. Bostwick, and H. Mukhtar, “Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma,” The Prostate, vol. 42, no. 1, pp. 73–78, 2000. View at Google Scholar
  42. M. Majima, H. Amano, and I. Hayashi, “Prostanoid receptor signaling relevant to tumor growth and angiogenesis,” Trends in Pharmacological Sciences, vol. 24, no. 10, pp. 524–529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Veitonmäki, T. L. Tammela, A. Auvinen, and T. J. Murtola, “Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level,” European Journal of Cancer, vol. 49, no. 4, pp. 938–945, 2013. View at Publisher · View at Google Scholar
  44. M. I. Patel, K. Subbaramaiah, B. Du et al., “Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism,” Clinical Cancer Research, vol. 11, no. 5, pp. 1999–2007, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A.-L. Hsu, T.-T. Ching, D.-S. Wang, X. Song, V. M. Rangnekar, and C.-S. Chen, “The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2,” The Journal of Biological Chemistry, vol. 275, no. 15, pp. 11397–11403, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. S. K. Kulp, Y.-T. Yang, C.-C. Hung et al., “3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells,” Cancer Research, vol. 64, no. 4, pp. 1444–1451, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Inoue, S. Anai, S. Onishi et al., “Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model,” BMC Urology, vol. 13, article 1, 2013. View at Publisher · View at Google Scholar
  48. X. Zheng, X.-X. Cui, Z. Gao et al., “Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence,” Cancer Prevention Research, vol. 3, no. 1, pp. 114–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Abedinpour, V. T. Baron, J. Welsh, and P. Borgström, “Regression of prostatetumors upon combination of hormone ablation therapy and celecoxib in vivo,” The Prostate, vol. 71, no. 8, pp. 813–823, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. B. A. Narayanan, N. K. Narayanan, B. Pittman, and B. S. Reddy, “Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model,” Clinical Cancer Research, vol. 10, no. 22, pp. 7727–7737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Gupta, V. M. Adhami, M. Subbarayan et al., “Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model,” Cancer Research, vol. 64, no. 9, pp. 3334–3343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. B. A. Narayanan, N. K. Narayanan, B. Pttman, and B. S. Reddy, “Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition,” The Prostate, vol. 66, no. 3, pp. 257–265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. B. A. Narayanan, M. S. Condon, M. C. Bosland, N. K. Narayanan, and B. S. Reddy, “Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s),” Clinical Cancer Research, vol. 9, no. 9, pp. 3503–3513, 2003. View at Google Scholar · View at Scopus
  54. J. S. Royle, J. A. Ross, I. Ansell, P. Bollina, D. N. Tulloch, and F. K. Habib, “Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3,” The Journal of Urology, vol. 172, no. 1, pp. 338–344, 2004. View at Google Scholar · View at Scopus
  55. S. Huguenin, J. Fleury-Feith, L. Kheuang et al., “Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines,” The Prostate, vol. 61, no. 2, pp. 132–141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. G. D. Stewart, J. Nanda, D. J. G. Brown, A. C. P. Riddick, J. A. Ross, and F. K. Habib, “NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway,” International Journal of Cancer, vol. 124, no. 1, pp. 223–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Lu, H. N. Tinsley, A. Keeton, Z. Qu, G. A. Piazza, and Y. Li, “Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation,” European Journal of Pharmacology, vol. 602, no. 1, pp. 8–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Google Scholar · View at Scopus
  59. J. E. Nelson and R. E. Harris, “Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study,” Oncology Reports, vol. 7, no. 1, pp. 169–170, 2000. View at Google Scholar · View at Scopus
  60. L. A. Habel, W. Zhao, and J. L. Stanford, “Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US,” Cancer Causes & Control, vol. 13, no. 5, pp. 427–434, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. M. R. Smith, J. Manola, D. S. Kaufman, W. K. Oh, G. J. Bubley, and P. W. Kantoff, “Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2723–2728, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. E. Norrish, R. T. Jackson, and C. U. McRae, “Non-steroidal anti-inflammatory drugs and prostate cancer progression,” International Journal of Cancer, vol. 77, no. 4, pp. 511–515, 1998. View at Google Scholar
  63. C. A. Salinas, E. M. Kwon, L. M. Fitzgerald et al., “Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk,” American Journal of Epidemiology, vol. 172, no. 5, pp. 578–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. R. O. Roberts, D. J. Jacobson, C. J. Girman, T. Rhodes, M. M. Lieber, and S. J. Jacobsen, “A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer,” Mayo Clinic Proceedings, vol. 77, no. 3, pp. 219–225, 2002. View at Google Scholar · View at Scopus
  65. R. S. Pruthi, J. E. Derksen, and D. Moore, “A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy,” BJU International, vol. 93, no. 3, pp. 275–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Menezes, H. Swede, R. Niles, and K. B. Moysich, “Regular use of aspirin and prostate cancer risk (United States),” Cancer Causes & Control, vol. 17, no. 3, pp. 251–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Bosetti, R. Talamini, E. Negri, S. Franceschi, M. Montella, and C. la Vecchia, “Aspirin and the risk of prostate cancer,” European Journal of Cancer Prevention, vol. 15, no. 1, pp. 43–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. M. J. S. Langman, K. K. Cheng, E. A. Gilman, and R. J. Lancashire, “Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database,” British Medical Journal, vol. 320, no. 7250, pp. 1642–1646, 2000. View at Google Scholar · View at Scopus
  69. M. F. Leitzmann, M. J. Stampfer, J. Ma et al., “Aspirin use in relation to risk of prostate cancer,” Cancer Epidemiology Biomarkers & Prevention, vol. 11, no. 10, pp. 1108–1111, 2002. View at Google Scholar · View at Scopus